Micronutrient form, gut luminal chemistry, and transporter competition determine what fraction of a dose is actually absorbed
Not all "10 mg of iron" or "500 mg of calcium" are equal. The chemical form a micronutrient is delivered in — heme vs non-heme iron, carbonate vs citrate calcium, chelated vs inorganic trace minerals — sets the theoretical maximum bioavailability before any digestive or dietary factor is even considered.
Iron forms: • Ferrous sulfate (FeSO₄·7H₂O): 20% elemental iron by weight, inexpensive, well-absorbed relative to other salts but GI side effects (nausea, constipation) common • Ferrous gluconate/fumarate: similar bioavailability to sulfate, marginally better tolerated • Ferric citrate / iron polysaccharide complex: lower direct solubility, requires more extensive luminal processing • Heme iron (as in myoglobin/hemoglobin from meat): absorbed via a completely distinct receptor-mediated pathway, largely unaffected by phytate/tannin inhibition
Calcium forms: • Calcium carbonate (40% elemental Ca): cheapest, most concentrated, but requires gastric acid for dissolution — poorly absorbed on an empty stomach or with acid-suppressing medication (PPIs) • Calcium citrate (21% elemental Ca): soluble independent of gastric pH, better absorbed in achlorhydric or PPI-treated patients, more expensive per elemental mg • Calcium citrate-malate (used in fortified juices): highest relative bioavailability among common forms, ~35% fractional absorption
General principle: bioavailability and elemental concentration trade off — the most concentrated, cheapest forms (carbonate, sulfate) tend to have the most pH/matrix-dependent absorption, while chelated forms are more expensive but more robust.
Before any transporter can act, a mineral salt must dissolve into free ionic form in gastric acid. This single step explains why proton-pump inhibitor (PPI) use is one of the most common causes of iron and calcium-carbonate malabsorption in clinical practice.
Gastric acid (HCl, pH 1.5-3.5 fasting) performs two essential functions for mineral bioavailability:
1. Salt dissociation: ionic mineral salts (ferrous sulfate, calcium carbonate) dissolve into free Mⁿ⁺ ions only in an acidic environment. Calcium carbonate solubility drops by roughly half in patients with reduced acid secretion (atrophic gastritis, PPI therapy, post-bariatric surgery).
2. Iron redox conversion: dietary non-heme iron exists predominantly as ferric (Fe³⁺), which has very low solubility at neutral pH and cannot use the DMT1 transporter. Gastric acid combined with duodenal cytochrome B (DCYTB), a ferrireductase on the brush border, converts Fe³⁺ → Fe²⁺ (ferrous), the only form DMT1 transports. Ascorbic acid also performs this reduction non-enzymatically.
Clinical implication: patients on chronic PPI therapy show 30-50% reductions in non-heme iron and calcium carbonate absorption — a well-documented cause of iatrogenic iron deficiency and reduced fracture-protective calcium intake, prompting recommendations to switch to calcium citrate (acid-independent) in this population.
Once solubilized, a mineral ion enters a chemically hostile lumen crowded with competing food-matrix ligands. Phytic acid and polyphenols can reduce non-heme iron and zinc absorption by 4-10 fold, while ascorbic acid and animal tissue can reverse much of that inhibition — the single largest source of variability in real-world micronutrient bioavailability.
Inhibitors: • Phytic acid (inositol hexaphosphate, abundant in whole grains, legumes, nuts): forms highly insoluble complexes with Fe²⁺/Fe³⁺, Zn²⁺, and Ca²⁺ via its six phosphate groups — even small amounts (25-50 mg) can reduce iron absorption by half • Polyphenols/tannins (tea, coffee, cocoa, red wine): form insoluble iron-tannate complexes; drinking tea with a meal can reduce non-heme iron absorption by 60% • Oxalate (spinach, rhubarb): binds calcium into insoluble calcium oxalate, largely explaining why spinach calcium is poorly bioavailable (~5%) despite high total content • Excess zinc/calcium: compete with iron/each other for shared divalent metal transporters, causing absorptive competition at high supplemental doses taken together
Enhancers: • Ascorbic acid: reduces Fe³⁺→Fe²⁺ and forms a soluble, chelatable ferrous-ascorbate complex resistant to phytate binding; 25-50 mg vitamin C taken with a meal can offset moderate phytate inhibition 3-4 fold • "Meat, fish, poultry (MFP) factor": an incompletely characterized effect of animal tissue peptides that enhances non-heme iron absorption from the same meal by roughly 2-fold • Organic acids (citric, malic from fruit): mild chelating and solubilizing effect on iron and calcium
Because inhibitor and enhancer effects operate within a single meal, timing matters more than total daily intake for non-heme iron: separating high-phytate/tannin foods (whole grain bread, tea) from the iron-containing meal by 1-2 hours, or pairing iron intake with vitamin C, can shift absorption by 3-10 fold without changing the dose at all.
Solubilized minerals still must cross the intestinal brush border via specific transport proteins, each with its own kinetics, saturability, and regulatory control — explaining why very high single doses of iron or calcium show diminishing fractional absorption.
Non-heme iron — DMT1 pathway: • Divalent Metal Transporter 1 (DMT1/SLC11A2) on the duodenal brush border co-transports Fe²⁺ with H⁺ down a proton gradient • Saturable, Michaelis-Menten kinetics — at very high doses, transporter saturation caps fractional absorption regardless of luminal availability • Intracellular iron exported to plasma via ferroportin, regulated by hepcidin (the master iron-regulatory hormone) — hepcidin is upregulated by inflammation and adequate iron stores, actively suppressing further absorption
Heme iron — HCP1 pathway: • Heme Carrier Protein 1 (HCP1/SLC46A1) mediates receptor-assisted endocytosis of the intact heme molecule • Once inside the enterocyte, heme oxygenase (HO-1) cleaves the porphyrin ring to release Fe²⁺, which then joins the same ferroportin export pathway • Because heme enters as an intact metalloporphyrin, it is essentially immune to phytate/tannin luminal binding — the biological basis for heme iron's consistently higher bioavailability across diverse diets
Calcium — dual pathway: • TRPV6 channel + calbindin-D9k + PMCA1b pump: active, saturable, transcellular pathway; calbindin expression is upregulated by 1,25-dihydroxyvitamin D (calcitriol), making this pathway vitamin-D dependent and dominant at low-to-moderate calcium doses • Paracellular diffusion: passive, non-saturable, becomes proportionally more important at high calcium doses (>500 mg) — explaining why splitting calcium supplements into smaller doses across the day improves total fractional absorption versus one large dose
The final, clinically relevant number — fractional bioavailability — is the product of every upstream step: chemical form, gastric solubilization, luminal matrix competition, and transporter saturation. This integrated view explains the 10-fold range seen across real dietary and supplemental scenarios.
Net fractional bioavailability can be modeled as a product of sequential efficiencies:
F_net = F_solubilization × F_matrix-survival × F_transporter-uptake
For non-heme iron, each term varies substantially with meal composition, giving a realistic range of 2-20% fractional absorption for the identical elemental dose depending entirely on what it is consumed with. For heme iron, F_matrix-survival ≈ 1 (near-total resistance to phytate/tannin), collapsing the range to a much narrower 15-35% window — the central reason iron-deficiency anemia is far more prevalent in populations with low meat intake and high cereal-based diets.
Formulation science applies these principles directly: • Iron fortification programs (e.g. NaFeEDTA-fortified salt/soy sauce in phytate-rich diet regions) use chelated iron forms specifically because the EDTA ligand protects Fe²⁺ from phytate binding, roughly doubling absorption versus ferrous sulfate in the same high-phytate meal • Calcium supplement labeling recommendations to split doses (≤500 mg elemental Ca per dose) directly reflect TRPV6 transporter saturation kinetics • Multi-mineral supplements are formulated to stagger iron and calcium/zinc dosing (or use enteric-release delivery) to avoid competitive transporter inhibition between co-administered divalent cations
A landmark stable-isotope absorption study (Hallberg & Hulthén, Am J Clin Nutr) demonstrated that the same 15 mg elemental iron dose yielded anywhere from 0.5 mg to 3.5 mg of actually absorbed iron depending solely on meal composition — a sevenfold range from matrix effects alone, larger than the difference between most supplemental iron salts.